WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999006396) IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/006396    International Application No.:    PCT/US1998/015592
Publication Date: 11.02.1999 International Filing Date: 29.07.1998
IPC:
C07D 401/04 (2006.01), C07D 403/04 (2006.01), C07D 471/04 (2006.01), C07D 487/04 (2006.01), C07D 495/04 (2006.01)
Applicants: WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road Morris Plains, NJ 07950 (US) (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HR, HU, ID, IE, IL, IS, IT, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW only).
BRIDGES, Alexander, James [GB/US]; (US) (For US Only)
Inventors: BRIDGES, Alexander, James; (US)
Agent: RYAN, M., Andrea; Warner-Lambert Company 201 Tabor Road Morris Plains, NJ 07950 (US)
Priority Data:
60/054,061 29.07.1997 US
Title (EN) IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES
(FR) INHIBITEURS BICYCLIQUES IRREVERSIBLES DE TYROSINE KINASES
Abstract: front page image
(EN)The present invention provides compounds that are irreversible inhibitors of tyrosine kinases of formula (I) or (II). Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases. In formulas (I) and (II), Z, X, Y or R?13¿ are as defined in the description.
(FR)La présente invention se rapporte à des composés qui sont des inhibiteurs irréversibles de tyrosine kinases et sont représentés par les formules (I) ou (II). Elle se rapporte également à une méthode de traitement du cancer, de la resténose, de l'athérosclérose, de l'endométriose et du psoriasis, ainsi qu'à une composition pharmaceutique contenant un composé qui est un inhibiteur irréversible de tyrosine kinases. Dans les formules (I) et (II), X, Y, Z et R?13¿ sont tels que définis dans les spécifications de l'invention.
Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)